Eli lilly and company LLY.US Overview
LLY AI Analysis & Strategy
Value: 3
With average fundamentals, the stock maintains stable profits, indicating reliability.
Dividend: 5
With the stock maintains stable profits, the stock maintains stable profits, indicating reliability.
Whale Interest: 5
BonusInstitutional holdings are relatively concentrated, hinting at stable long-term growth.
Analysis Conclusion
The stock holds a moderate value rating. If you have positions, consider retaining; for new ones, wait for a value score above 4.
LLY Current Performance
-2.84%
Eli lilly and company
-0.35%
Avg of Sector
-0.22%
S&P500
LLY Key Information
LLY Financial Forecast
Unit : USD
LLY Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 3.34 | 29.5% | 2.5% | 12.73B | 45.2% | 0.5% | 32.6% |
| 2024Q3 | 5.32 | 113.7% | -2.4% | 13.53B | 44.7% | 0.4% | 8.5% |
| 2024Q2 | 1.18 | 1,080% | -19.7% | 11.44B | 20.4% | -5.4% | 26.3% |
| 2024Q1 | 3.92 | 85.8% | 50.8% | 11.3B | 36% | 13.2% | 25.6% |
| 2023Q4 | 2.58 | 59.3% | 4.9% | 8.77B | 26% | -1.9% | 23.4% |
LLY Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.